Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 7/20 | 0.63 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.63 |
| ▸ | PARP1 | P09874 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | METAP2 | P50579 | 1/20 | 0.61 |
| ▸ | METAP1 | P53582 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169443 | 1.00 | NPC1 (1.00) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL29764050 | 1.00 | NPC1 (1.00) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL12758425 | 0.85 | ALDH1A1 (0.73) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL20665799 | 0.84 | ALDH1A1 (0.73) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL28948385 | 0.83 | NPC1 (0.70) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL20665778 | 0.83 | ALDH1A1 (0.70) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL6695759 | 0.82 | TNKS2 (0.81) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL11383437 | 0.81 | NPC1 (0.67) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL12758408 | 0.80 | TNKS (0.67) | NPC1RAB9AALDH1A1LMNAHTT | |
| SCHEMBL20665801 | 0.80 | NPC1 (0.65) | NPC1RAB9AALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| CN-113185468-B | Method for synthesizing quinazolinone through photocatalysis | 上海橡实化学有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210246109-A1 | POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2021-08-12 | — | — | US | disclosed |
| CN-113185468-A | Method for synthesizing quinazolinone through photocatalysis | 上海橡实化学有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-20110124649-A1 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| WO-2009064388-A2 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | LIU JUN O (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| EP-0135975-B1 | QUINAZOLINE AND ISOQUINOLINE DERIVATIVES | AKZO N.V. (NL) | 1988-09-14 | — | — | EP | disclosed |
| US-4694000-A | Quinazoline and isoquinoline derivatives | AKZO N.V. (NL) | 1987-09-15 | — | — | US | disclosed |
| WO-1985001501-A1 | QUINAZOLINE AND ISOQUINOLINE DERIVATIVES | AKZO N.V. (NL) | 1985-04-11 | — | — | WO | disclosed |
| EP-0135975-A2 | Quinazoline and isoquinoline derivatives | AKZO N.V. (NL) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | NPC1 2606/4885RAB9A 36/4885ALDH1A1 3448/4885 |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | NPC1 4122/4885RAB9A 2821/4885ALDH1A1 4582/4885 |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | CYP2A6, CYP2B6, XPO6 | NPC1 1604/4885RAB9A 2997/4885ALDH1A1 1360/4885 |
| US-20210246109-A1 | POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP1B1, CYP27A1 | NPC1 751/4885RAB9A 1418/4885ALDH1A1 87/4885 |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | NPC1 2606/4885RAB9A 36/4885ALDH1A1 3448/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | NPC1 2606/4885RAB9A 36/4885ALDH1A1 3448/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | NPC1 2606/4885RAB9A 36/4885ALDH1A1 3448/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | NPC1 2606/4885RAB9A 36/4885ALDH1A1 3448/4885 |
| US-20110124649-A1 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | METAP1, DNPEP, METAP2 | NPC1 756/4885RAB9A 2879/4885ALDH1A1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.